000138708 001__ 138708
000138708 005__ 20240722104653.0
000138708 0247_ $$2doi$$a10.1016/j.cct.2016.05.007
000138708 0247_ $$2pmid$$apmid:27261170
000138708 0247_ $$2ISSN$$a1551-7144
000138708 0247_ $$2ISSN$$a1559-2030
000138708 0247_ $$2altmetric$$aaltmetric:8489139
000138708 037__ $$aDZNE-2020-05030
000138708 041__ $$aEnglish
000138708 082__ $$a610
000138708 1001_ $$0P:(DE-HGF)0$$aZimmer, P.$$b0$$eCorresponding author
000138708 245__ $$aImpact of aerobic exercise training during chemotherapy on cancer related cognitive impairments in patients suffering from acute myeloid leukemia or myelodysplastic syndrome - Study protocol of a randomized placebo-controlled trial.
000138708 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2016
000138708 264_1 $$2Crossref$$3print$$bElsevier BV$$c2016-07-01
000138708 3367_ $$2DRIVER$$aarticle
000138708 3367_ $$2DataCite$$aOutput Types/Journal article
000138708 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1721637961_12030
000138708 3367_ $$2BibTeX$$aARTICLE
000138708 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000138708 3367_ $$00$$2EndNote$$aJournal Article
000138708 520__ $$aCancer related cognitive impairments (CRCI) are frequently reported by patients prior to, during and after medical treatment. Although this cognitive decline severely affects patients' quality of life, little is known about effective treatments. Exercise programs represent a promising supportive strategy in this field. However, evidence is sparse and existing studies display methodological limitations. In the planned study, 83 men and women newly diagnosed with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) will be randomized into one of three treatment groups. During 4weeks of induction chemotherapy with Anthracycline and Cytarabin patients allocated to exercise group will cycle 3×/week for 30min at moderate to vigorous intensity on an ergometer. Patients allocated to placebo group will receive a supervised myofascial release training (3×/week, approx. 30min) and patients at control group will get usual care. As primary endpoints a cognitive test battery will be conducted measuring performances depending on verbal/spatial memory and executive functioning. Secondary endpoints will be self-perceived cognitive functioning, as well as neurotrophic and inflammatory serum markers. All assessments will be conducted immediately after hospitalization and before chemotherapy is commenced, immediately before discharge of hospital after 4-5weeks as well as before continuing medical treatment 3-4weeks after discharge. This will be the first study investigating the impact of an aerobic exercise training on CRCI in AML/MDS patients. We hope that the study design and the state-of-the-art assessments will help to increase knowledge about CRCI in general and exercise as potential treatment option in this under investigated population.
000138708 536__ $$0G:(DE-HGF)POF3-342$$a342 - Disease Mechanisms and Model Systems (POF3-342)$$cPOF3-342$$fPOF III$$x0
000138708 542__ $$2Crossref$$i2016-07-01$$uhttps://www.elsevier.com/tdm/userlicense/1.0/
000138708 588__ $$aDataset connected to CrossRef, PubMed,
000138708 650_7 $$2NLM Chemicals$$aAnthracyclines
000138708 650_7 $$004079A1RDZ$$2NLM Chemicals$$aCytarabine
000138708 650_2 $$2MeSH$$aAnthracyclines: administration & dosage
000138708 650_2 $$2MeSH$$aAntineoplastic Combined Chemotherapy Protocols: adverse effects
000138708 650_2 $$2MeSH$$aBicycling
000138708 650_2 $$2MeSH$$aCognitive Dysfunction: etiology
000138708 650_2 $$2MeSH$$aCognitive Dysfunction: prevention & control
000138708 650_2 $$2MeSH$$aCognitive Dysfunction: psychology
000138708 650_2 $$2MeSH$$aCognitive Dysfunction: rehabilitation
000138708 650_2 $$2MeSH$$aCytarabine: administration & dosage
000138708 650_2 $$2MeSH$$aExecutive Function
000138708 650_2 $$2MeSH$$aExercise Therapy: methods
000138708 650_2 $$2MeSH$$aHumans
000138708 650_2 $$2MeSH$$aLeukemia, Myeloid, Acute: complications
000138708 650_2 $$2MeSH$$aLeukemia, Myeloid, Acute: drug therapy
000138708 650_2 $$2MeSH$$aLeukemia, Myeloid, Acute: psychology
000138708 650_2 $$2MeSH$$aMyelodysplastic Syndromes: complications
000138708 650_2 $$2MeSH$$aMyelodysplastic Syndromes: drug therapy
000138708 650_2 $$2MeSH$$aMyelodysplastic Syndromes: psychology
000138708 650_2 $$2MeSH$$aNeuropsychological Tests
000138708 650_2 $$2MeSH$$aSpatial Memory
000138708 650_2 $$2MeSH$$aTreatment Outcome
000138708 7001_ $$aOberste, M.$$b1
000138708 7001_ $$aBloch, W.$$b2
000138708 7001_ $$aSchenk, A.$$b3
000138708 7001_ $$aJoisten, N.$$b4
000138708 7001_ $$aHartig, P.$$b5
000138708 7001_ $$0P:(DE-HGF)0$$aWolf, F.$$b6
000138708 7001_ $$aBaumann, F. T.$$b7
000138708 7001_ $$0P:(DE-2719)2810535$$aGarthe, A.$$b8$$udzne
000138708 7001_ $$aHallek, M.$$b9
000138708 7001_ $$aElter, T.$$b10
000138708 77318 $$2Crossref$$3journal-article$$a10.1016/j.cct.2016.05.007$$b : Elsevier BV, 2016-07-01$$p1-5$$tContemporary Clinical Trials$$v49$$x1551-7144$$y2016
000138708 773__ $$0PERI:(DE-600)2176813-4$$a10.1016/j.cct.2016.05.007$$gVol. 49, p. 1 - 5$$p1-5$$q49<1 - 5$$tContemporary clinical trials$$v49$$x1551-7144$$y2016
000138708 8564_ $$uhttps://pub.dzne.de/record/138708/files/DZNE-2020-05030_Restricted.pdf
000138708 8564_ $$uhttps://pub.dzne.de/record/138708/files/DZNE-2020-05030_Restricted.pdf?subformat=pdfa$$xpdfa
000138708 909CO $$ooai:pub.dzne.de:138708$$pVDB
000138708 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810535$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000138708 9131_ $$0G:(DE-HGF)POF3-342$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vDisease Mechanisms and Model Systems$$x0
000138708 9141_ $$y2016
000138708 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000138708 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCONTEMP CLIN TRIALS : 2017
000138708 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000138708 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000138708 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000138708 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000138708 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000138708 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000138708 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000138708 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000138708 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000138708 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000138708 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000138708 9201_ $$0I:(DE-2719)1740001$$kAG Garthe$$lTechnology Platform Neurobiology of Behaviour$$x0
000138708 980__ $$ajournal
000138708 980__ $$aVDB
000138708 980__ $$aI:(DE-2719)1740001
000138708 980__ $$aUNRESTRICTED